Cellogen Therapeutics develops third and fourth generation CAR T-cell therapies and gene editing techniques, including CRISPR, to treat hematological malignancies and genetic blood disorders. The company aims to provide long-lasting cures by targeting the root causes of diseases, significantly improving patient outcomes and reducing treatment costs.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for hematological malignancies, genetic blood disorders, and solid tumors often fall short of providing long-lasting cures, leading to disease recurrence and the need for ongoing, expensive management. Existing CAR T-cell therapies can be limited by antigen escape and high costs, while gene editing techniques face challenges in achieving efficient and precise correction of genetic defects.
Solution
Cellogen Therapeutics is developing advanced third and fourth generation CAR T-cell therapies and gene editing techniques, including CRISPR, to provide curative treatments for cancers and genetic blood disorders. Their CAR T-cell therapies are designed with enhanced precision and potency, utilizing bi-specific targeting to reduce the risk of antigen escape. The company's gene manipulation programs focus on reprogramming or replacing faulty hematopoietic stem cells to address the root cause of diseases like sickle cell anemia and thalassemia. By developing indigenous products, Cellogen aims to significantly reduce treatment costs and improve patient access to these advanced therapies.
Target Audience
The primary target audience includes patients with hematological malignancies (leukemia, lymphoma), genetic blood disorders (sickle cell disease, thalassemia), and solid tumors, as well as the healthcare providers and institutions that treat them.
Features
- Bi-specific CAR T-cell therapies targeting two different antigens (CD19 and CD20) simultaneously to minimize antigen escape.
- Advanced cellular engineering methods and gene therapy-based approaches for curative treatments.
- CRISPR-based gene editing for precise correction of genetic defects in hematopoietic stem cells.
- Development of autologous cell therapies for solid tumors.
- Focus on patient-friendly and long-lasting cures.
- Indigenous research and development to reduce treatment costs.